Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The “printers” are portable, automated messenger RNA (mRNA) production units, which Elon Musk referred to as “RNA microfactories.”
Annexon, based in South San Francisco, closed on a $100 million Series C financing led by Redmile Group.
Meet with regulatory affairs professionals early and often. That’s the message from Neelu Gibson, VP, regulatory affairs, at BD, speaking at Biocom’s June virtual meeting, “Regulatory Affairs…Engagement Do’s & Don’ts.”
Amidst the pandemic, the biopharma industry continues to surge ahead. Jobs look plentiful. Check out these companies that have made recent job announcement expansions.
Cambridge, Massachusetts-based Carmine Therapeutics inked a research collaboration deal with Japan’s Takeda Pharmaceutical to develop and commercialize non-viral gene therapies for two rare diseases.
Interferons are proteins produced by the body to fight viral infections by inhibiting its replication in the body.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
This was on top of Syncona’s previously announced Series C investment in Freeline of $40 million, with another $80 million in new capital.
Specifically, the report indicated that biotechnology companies drove the healthcare industry to make up almost two-thirds of IPO activity in the second quarter of 2020.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.